DE69327432T2 - Heilmittel für wunden und hämorrhoiden - Google Patents

Heilmittel für wunden und hämorrhoiden

Info

Publication number
DE69327432T2
DE69327432T2 DE69327432T DE69327432T DE69327432T2 DE 69327432 T2 DE69327432 T2 DE 69327432T2 DE 69327432 T DE69327432 T DE 69327432T DE 69327432 T DE69327432 T DE 69327432T DE 69327432 T2 DE69327432 T2 DE 69327432T2
Authority
DE
Germany
Prior art keywords
beraprost
administered
hemorrhoids
administration
wounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69327432T
Other languages
German (de)
English (en)
Other versions
DE69327432D1 (de
Inventor
Tsutomu Nakamura
Toshiaki Cent. Research Lab. Kaken Pharm. Okuda
Makoto Okumura
Motoyuki Yamija
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Kaken Pharmaceutical Co Ltd
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Toray Industries Inc filed Critical Kaken Pharmaceutical Co Ltd
Publication of DE69327432D1 publication Critical patent/DE69327432D1/de
Application granted granted Critical
Publication of DE69327432T2 publication Critical patent/DE69327432T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69327432T 1992-02-07 1993-02-05 Heilmittel für wunden und hämorrhoiden Expired - Fee Related DE69327432T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2280892 1992-02-07
JP18986792 1992-06-24
PCT/JP1993/000151 WO1993015739A1 (fr) 1992-02-07 1993-02-05 Remede destine aux blessures ou aux hemorroides

Publications (2)

Publication Number Publication Date
DE69327432D1 DE69327432D1 (de) 2000-02-03
DE69327432T2 true DE69327432T2 (de) 2000-05-18

Family

ID=26360087

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69327432T Expired - Fee Related DE69327432T2 (de) 1992-02-07 1993-02-05 Heilmittel für wunden und hämorrhoiden

Country Status (8)

Country Link
US (3) US5403867A (enExample)
EP (1) EP0583482B1 (enExample)
JP (1) JP3209427B2 (enExample)
AT (1) ATE188119T1 (enExample)
CA (1) CA2107669C (enExample)
DE (1) DE69327432T2 (enExample)
TW (1) TW234691B (enExample)
WO (1) WO1993015739A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
JP3209427B2 (ja) * 1992-02-07 2001-09-17 科研製薬株式会社 創傷または痔疾治療剤
EP0731712A4 (en) * 1993-10-29 2005-11-09 Univ Boston PHYSIOLOGICALLY STABLE COMPOSITIONS OF BUTYRIC ACID, SALTS AND BUTYRIC ACID DERIVATIVES AS ANTINEOPLASTIC AGENTS
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
IT1269634B (it) * 1994-05-06 1997-04-08 Indena Spa Medicamento topico ad attivita' cicatrizzante
CA2191601A1 (en) * 1994-06-02 1995-12-14 Hirofumi Tanabe Pharmaceutical composition for treating peripheral circulation disorder
PT742011E (pt) * 1994-11-17 2002-10-31 Toray Industries Preparacao que pode ser absorvida por via percutanea
CA2188931C (en) * 1995-02-27 2007-09-11 Reiji Kasukawa Agent for treating cor pulmonale
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5869059A (en) * 1996-01-16 1999-02-09 Mon's Tea Partnership Herbal composition for hemorrhoid treatment
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
ES2309380T3 (es) * 2002-08-09 2008-12-16 Taisho Pharmaceutical Co., Ltd Agente antipruritico.
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
MXPA05010552A (es) 2003-04-02 2005-11-23 Nexmed Holdings Inc Composiciones de prostaglandina y su uso para el tratamiento de vasoespasmos.
JP4157889B2 (ja) * 2003-06-25 2008-10-01 有限会社 循環器研究所 性交機能改善用外用製剤
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
US8618068B2 (en) 2009-12-08 2013-12-31 Trustees Of Boston University Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
JP2014510156A (ja) 2011-04-07 2014-04-24 ネクスメッド ホールディングス，インコーポレイテッド レイノー病を治療する方法および組成物
WO2014164886A1 (en) * 2013-03-13 2014-10-09 Allergan, Inc. Prostanoid receptor agonist compounds and their use
CN109715173A (zh) 2016-07-15 2019-05-03 维拉克塔治疗公司 供基于nk细胞的疗法使用的hdac抑制剂
CN114206447A (zh) 2019-05-31 2022-03-18 维拉克塔附属公司 用组蛋白脱乙酰基酶抑制剂治疗病毒相关的癌症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4025645A (en) * 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
GB1595056A (en) * 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
JPS5391110A (en) * 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
DE3162659D1 (en) * 1980-07-22 1984-04-19 Ono Pharmaceutical Co 9,11-methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof
DE3631169A1 (de) * 1986-09-11 1988-03-24 Schering Ag Prostacyclinderivate enthaltende mittel fuer die topische anwendung
DE3886936T2 (de) * 1987-10-16 1994-04-28 Toray Industries 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
JPH0311017A (ja) * 1989-06-06 1991-01-18 Green Cross Corp:The プロスタグランジンｅ↓１含有薬剤組成物
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
JP3209427B2 (ja) * 1992-02-07 2001-09-17 科研製薬株式会社 創傷または痔疾治療剤
AU669783B2 (en) * 1993-02-03 1996-06-20 Teijin Limited Dermatologic preparation composition containing prostacyclinas active ingredient

Also Published As

Publication number Publication date
EP0583482A4 (en) 1995-05-03
TW234691B (enExample) 1994-11-21
DE69327432D1 (de) 2000-02-03
JP3209427B2 (ja) 2001-09-17
CA2107669C (en) 2004-06-01
US5852050A (en) 1998-12-22
CA2107669A1 (en) 1993-08-08
EP0583482B1 (en) 1999-12-29
US5403867A (en) 1995-04-04
WO1993015739A1 (fr) 1993-08-19
ATE188119T1 (de) 2000-01-15
EP0583482A1 (en) 1994-02-23
US5679707A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
DE69327432T2 (de) Heilmittel für wunden und hämorrhoiden
DE68902649T2 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
DE3788984T2 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
DE3689384T2 (de) Arzneimittel zur topischen Anwendung.
DE3507024C2 (de) Lösung zur Augenbehandlung
DE68912459T2 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
DE3310079A1 (de) Topische ophthalmische arzneimittel
DE69822295T2 (de) Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen
WO2005063224A1 (de) Topische zubereitungen enthaltend dimethylsulfoxid und dexpanthenol
DE60130661T2 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69208941T2 (de) Augenpräparate mit verlängerter Freigabe
DE69105349T2 (de) Behandlung von intraocularem Druck mit einer synergistischen Kombination zur ophthalmischen Verwendung.
DE69323202T2 (de) Ophthalmologische zubereitungen
DE69423773T2 (de) Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit-formulierungen
DE69004532T2 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
DE2611183C2 (de) Stabilisierte Formulierung prostaglandinartiger Arzneimittel des PGE-Typs
DE3440352A1 (de) Dry-eye-packung
EP0277462B1 (de) Verfahren zur Herstellung nasaler Lösungen enthaltend synthetisches Human calcitonin.
EP0585896A1 (de) Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
EP0068160B1 (de) Verwendung von 1-(p-Isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur Herstellung eines Arzneimittels zur Senkung des Augeninnendrucks
EP0450123B1 (de) Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung
EP0803254A1 (de) Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel
DE3880943T2 (de) Verwendung von thromboxan-a2-antagonisten zur herstellung eines arzneimittels zur wiederherstellung von post-ischaemischer myokard-dysfunktion.
EP0116358A1 (de) Komplexe von Prostaglandinen
DE69309461T2 (de) Zusammensetzung zur Beschleunigung der Wundheilung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TORAY INDUSTRIES, INC., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee